Search Nerddpedia

Alzheimer Disease

** Alzheimer disease is the world’s most common cause of dementia, a progressive brain disorder that robs individuals of memory, identity, and independence, affecting millions and driving urgent research and public‑health action. **CONTENT:** ## Overview Alzheimer disease (AD) is a chronic, progressive neurodegenerative disorder that accounts for **60‑80 % of all dementia cases** worldwide. First identified in the early 20th century, it is characterized pathologically by extracellular **amyloid‑β plaques** and intracellular **neurofibrillary tangles** composed of hyper‑phosphorylated tau protein. Clinically, patients experience a relentless decline in memory, language, visuospatial skills, and executive function, eventually losing the ability to perform basic activities of daily living. Globally, an estimated **55 million people** live with dementia, and AD is the leading contributor. In the United States alone, **≈ 6.2 million Americans aged ≥ 65** were living with AD in 2023, making it the **6th leading cause of death**. The disease imposes a staggering economic burden—U.S. health‑care costs exceeded **$300 billion** in 2022, with informal caregiving adding billions more. Despite these numbers, definitive disease‑modifying therapies remain elusive, underscoring the importance of early detection, risk‑reduction strategies, and supportive care. ## Background & Origins The story of Alzheimer disease begins with **Alois Alzheimer** (1864‑1915), a German psychiatrist and neuropathologist. In **1901**, Alzheimer began treating **Auguste Deter**, a 51‑year‑old woman who presented with progressive memory loss, language disturbances, and personality changes. After Deter’s death in **1906**, Alzheimer performed a post‑mortem examination, discovering **neuronal loss, cortical atrophy, and the hallmark plaques and tangles**. He presented these findings at the **Tübingen meeting of the German Psychiatric Society in 1906**, and later published the seminal paper **“Über eine eigenartige Erkrankung der Hirnrinde”** in **1910**, coining the term “Alzheimer’s disease” for this distinct clinical‑pathological entity. For decades the condition was considered a rare, “senile” form of dementia, but epidemiologic studies in the 1970s and 1980s revealed its true prevalence. The **NINCDS‑ADRDA criteria (1984)** and later the **DSM‑5 (2013)** standardized diagnosis, while advances in neuroimaging and cerebrospinal fluid biomarkers transformed AD from a purely clinical diagnosis to one supported by objective laboratory evidence. ## Major Achievements & Milestones **First cholinesterase inhibitor approval (1996):** The FDA approved **donepezil** (Aricept), the first drug shown to modestly improve cognition and daily functioning in mild‑to‑moderate AD, inaugurating a new therapeutic class. **Discovery of amyloid‑β peptide (1984):** **George Glenner** and **C. M. Glenner** isolated the 4‑kDa amyloid‑β fragment, confirming that amyloid plaques are composed of a specific peptide derived from the amyloid precursor protein (APP). This finding redirected research toward the “amyloid cascade hypothesis.” **Genetic breakthroughs (1991‑1995):** Mutations in **APP (1991)**, **PSEN1 (1995)**, and **PSEN2 (1995)** were linked to early‑onset familial AD, while the **APOE ε4 allele** was identified as the strongest genetic risk factor for late‑onset AD in **1995**, providing a genetic framework for risk stratification. **First disease‑modifying antibody (2021):** The FDA granted accelerated approval to **aducanumab (Aduhelm)**, an anti‑amyloid monoclonal antibody, marking the first therapy aimed at reducing amyloid plaques, albeit amid controversy over clinical efficacy. **Leqembi approval (2023):** **Lecanemab**, another anti‑amyloid antibody, received full FDA approval after the **CLARITY‑AD trial** demonstrated a statistically significant slowing of cognitive decline, offering renewed hope for disease‑modifying treatment. ## Timeline - **1906**: Alois Alzheimer presents the first case (Auguste Deter) at the Tübingen meeting. - **1910**: Publication of Alzheimer’s landmark paper describing plaques and tangles. - **1976**: First epidemiologic study (the “Nun Study”) highlights AD prevalence in aging populations. - **1984**: NINCDS‑ADRDA criteria standardize clinical diagnosis; amyloid‑β peptide identified. - **1996**: FDA approval of donepezil, the first cholinesterase inhibitor for AD. - **2003**: FDA approves memantine, an NMDA‑receptor antagonist for moderate‑to‑severe AD. - **2021**: FDA grants accelerated approval to aducanumab, the first amyloid‑targeting antibody. - **2023**: Lecanemab receives full FDA approval after robust phase‑III trial results. ## Impact & Legacy Alzheimer disease reshaped modern neurology, geriatrics, and public‑health policy. Its prevalence has driven **global initiatives** such as the **World Health Organization’s Global Action Plan on the Public Health Response to Dementia (2017‑2025)** and the **U.S. National Alzheimer’s Project Act (2009)**, which funds research, caregiver support, and public awareness campaigns. Culturally, AD has entered the collective consciousness through literature, film, and advocacy—think of the Pulitzer‑winning memoir **“The Longest Day”** or the Oscar‑winning documentary **“Alive Inside.”** The disease also spurred ethical debates about **diagnostic disclosure**, **advance directives**, and **clinical trial design**, influencing legislation on research funding and patient rights. ## Records & Notable Facts - **Prevalence:** AD accounts for **≈ 70 % of all dementia cases** worldwide. - **Mortality:** It is the **6th leading cause of death** in the United States (2022 CDC data). - **Economic impact:** U.S. health‑care expenditures for AD surpassed **$300 billion** in 2022. - **Gender disparity:** About **two‑thirds** of AD patients are women, reflecting longer life expectancy and possible biological factors. - **First diagnostic biomarker:** In **1995**, reduced cerebrospinal fluid (CSF) Aβ42 levels were shown to correlate with amyloid pathology, paving the way for modern biomarker‑driven diagnosis. > “The disease is a progressive loss of memory and other mental functions.” – **Alois Alzheimer** **INFOBOX:** - Full Name: Alzheimer disease (also Alzheimer’s disease) - Born: N/A - Died: N/A - Age: N/A - Nationality: N/A - Occupation: N/A - Active Years: 1906‑present (year first described) - Known For: Progressive neurodegeneration; amyloid‑β plaques & tau tangles - Awards: N/A - Spouse: N/A - Children: N/A - Height: N/A - Net Worth: N/A - World Records: N/A - Championships: N/A **FACTS:** - Birth Date: N/A (type: date) - Birth Place: N/A (type: location) - Death Date: N/A (type: date) - Career Start: 1906 (type: year) - Peak Achievement: Identification of amyloid‑β peptide (1984) (type: achievement) - Career Earnings: N/A (type: statistic) - World Record: N/A (type: record) - Famous Quote: “The disease is a progressive loss of memory and other mental functions.” (type: quote) - Fun Fact: Alzheimer disease accounts for **60‑80 % of all dementia** cases worldwide (type: trivia) - Legacy Stat: **≈ 6.2 million Americans** living with AD in 2023 (type: statistic) **TAGS:** alzheimer’s, dementia, neurodegeneration, neurology, genetics, epidemiology, treatment, history *This article is for educational purposes only. Always consult qualified health professionals for diagnosis, treatment, or medical advice.*